BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCDA BioCardia

Market Closed 07-31 16:00:00 EDT

0.8242

+0.0531

+6.89%

盘后0.8240

-0.0002-0.02%

18:43 EDT

High0.8249	Low0.7900	Vol127.93K
Open0.7900	D1 Closing0.7711	Amplitude4.53%
Mkt Cap12.27M	Tradable Cap9.91M	Total Shares14.88M
T/O103.59K	T/O Rate1.06%	Tradable Shares12.03M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCDA","market":"US","secType":"STK","nameCN":"BioCardia","latestPrice":0.8242,"timestamp":1785528000000,"preClose":0.7711,"halted":0,"volume":127925,"hourTrading":{"tag":"盘后","latestPrice":0.824,"preClose":0.8242,"latestTime":"18:43 EDT","volume":5938,"amount":4831.4985,"timestamp":1785537833851,"change":-0.0002,"changeRate":-0.000243,"amplitude":0.029362},"delay":0,"changeRate":0.06886266372714309,"floatShares":12025100,"shares":14884328,"eps":-0.946888,"marketStatus":"Market Closed","change":0.0531,"latestTime":"07-31 16:00:00 EDT","open":0.79,"high":0.8249,"low":0.79,"amount":103588.28575375,"amplitude":0.04526,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.946888,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.7711,"preHourTrading":{"tag":"盘前","latestPrice":0.8,"preClose":0.7711,"latestTime":"08:43 EDT","volume":138,"amount":108.81950808,"timestamp":1785501836873,"change":0.0289,"changeRate":0.037479,"amplitude":0.047465},"postHourTrading":{"tag":"盘后","latestPrice":0.824,"preClose":0.8242,"latestTime":"18:43 EDT","volume":5938,"amount":4831.4985,"timestamp":1785537833851,"change":-0.0002,"changeRate":-0.000243,"amplitude":0.029362},"volumeRatio":0.7103559026340565,"impliedVol":0.046,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BCDA","defaultTab":"news","newsList":[{"id":"2655601845","title":"BioCardia CEO Peter Altman Acquires 5,000 Common Shares Valued at $3,900","url":"https://stock-news.laohu8.com/highlight/detail?id=2655601845","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655601845?lang=en_us&edition=fundamental","pubTime":"2026-07-30 09:05","pubTimestamp":1785373544,"startTime":"0","endTime":"0","summary":"BioCardia CEO Peter Altman acquires 5,000 common shares valued at $3,900BioCardia President, CEO, director Peter Altman bought 5,000 common shares at a weighted average price of $0.78.Altman’s direct ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDLc89V9K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia CEO Peter Altman Acquires 5,000 Common Shares Valued at $3,900","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653024561","title":"Biocardia CEO Peter Altman Buys $415 of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2653024561","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653024561?lang=en_us&edition=fundamental","pubTime":"2026-07-21 04:16","pubTimestamp":1784578615,"startTime":"0","endTime":"0","summary":"BioCardia CEO Peter Altman buys $415 of common stockBioCardia President and CEO Peter Altman bought 500 common shares at $0.83 each.Altman’s direct holding rose to 368,885 BioCardia common shares.Disc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDLbtC5L3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Biocardia CEO Peter Altman Buys $415 of Common Stock","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651049694","title":"Biocardia CEO Peter Altman Acquires Common Shares Worth $3,749.80","url":"https://stock-news.laohu8.com/highlight/detail?id=2651049694","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651049694?lang=en_us&edition=fundamental","pubTime":"2026-07-16 04:41","pubTimestamp":1784148110,"startTime":"0","endTime":"0","summary":"BioCardia CEO Peter Altman acquires common shares worth $3,749.80BioCardia President, CEO, director Peter Altman bought 4,300 common shares in open-market purchases at weighted-average prices of $0.88","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL5mdVfF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Biocardia CEO Peter Altman Acquires Common Shares Worth $3,749.80","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650227130","title":"Biocardia CEO Peter Altman Acquires $7,175 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650227130","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650227130?lang=en_us&edition=fundamental","pubTime":"2026-07-11 06:19","pubTimestamp":1783721962,"startTime":"0","endTime":"0","summary":"BioCardia CEO Peter Altman acquires $7,175 of common sharesBioCardia President and CEO Peter Altman bought 7,500 common shares in open-market purchases.Purchases were priced between USD 0.9 and USD 0.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDLb7hDK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Biocardia CEO Peter Altman Acquires $7,175 of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650591301","title":"Biocardia CEO Peter Altman Acquires 5,400 Common Shares Worth $5,208.30","url":"https://stock-news.laohu8.com/highlight/detail?id=2650591301","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650591301?lang=en_us&edition=fundamental","pubTime":"2026-07-09 03:31","pubTimestamp":1783539080,"startTime":"0","endTime":"0","summary":"BioCardia CEO Peter Altman acquires 5,400 common shares worth $5,208.30BioCardia President and CEO Peter Altman bought 5,400 common shares at a weighted-average price of USD 0.96.Altman’s direct holdi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDLb37CVF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Biocardia CEO Peter Altman Acquires 5,400 Common Shares Worth $5,208.30","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646867823","title":"BioCardia Director Makes Bold Move With Fresh Insider Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2646867823","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646867823?lang=en_us&edition=fundamental","pubTime":"2026-06-25 10:05","pubTimestamp":1782353147,"startTime":"0","endTime":"0","summary":"New insider activity at BioCardia ( ($BCDA) ) has taken place on June 24, 2026. BioCardia director Simon H. Stertzer has increased his stake in the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/biocardia-director-makes-bold-move-with-fresh-insider-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/biocardia-director-makes-bold-move-with-fresh-insider-buy-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646841156","title":"Biocardia Director Simon H. Stertzer Acquires 109,200 Common Shares Valued at $103,584","url":"https://stock-news.laohu8.com/highlight/detail?id=2646841156","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646841156?lang=en_us&edition=fundamental","pubTime":"2026-06-25 06:17","pubTimestamp":1782339448,"startTime":"0","endTime":"0","summary":"BioCardia director Simon H. Stertzer acquires 109,200 common shares valued at $103,584BioCardia director Simon H. Stertzer reported open-market purchases totaling 109,200 common shares at weighted-ave","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL2KM9gF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Biocardia Director Simon H. Stertzer Acquires 109,200 Common Shares Valued at $103,584","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645434025","title":"BioCardia CEO Peter Altman acquires USD 2,043 of common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2645434025","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645434025?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:10","pubTimestamp":1782123024,"startTime":"0","endTime":"0","summary":"BioCardia President and CEO Peter Altman bought 2,300 common shares in open-market purchases priced at about $0.85 to $0.96.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL86Kx7B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia CEO Peter Altman acquires USD 2,043 of common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644089135","title":"BioCardia issues letter to shareholders on 2026 priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2644089135","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644089135?lang=en_us&edition=fundamental","pubTime":"2026-06-18 21:24","pubTimestamp":1781789097,"startTime":"0","endTime":"0","summary":"BioCardia (BCDA) announced that the Company’s Chief Executive Officer, Peter Altman, issued the following letter to shareholders. “Upon completion ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biocardia-issues-letter-to-shareholders-on-2026-priorities-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biocardia-issues-letter-to-shareholders-on-2026-priorities-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644085980","title":"BioCardia Outlines 2026 CardiAMP Strategy and Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2644085980","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644085980?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:40","pubTimestamp":1781786429,"startTime":"0","endTime":"0","summary":"The latest update is out from BioCardia ( ($BCDA) ). On June 18, 2026, BioCardia issued a shareholder letter outlining its 2026 strategic prioritie...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-outlines-2026-cardiamp-strategy-and-milestones?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-outlines-2026-cardiamp-strategy-and-milestones?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083641","title":"BioCardia targets Q4 2026 Japan PMDA filing for CardiAMP cell therapy approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083641","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644083641?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:04","pubTimestamp":1781784277,"startTime":"0","endTime":"0","summary":"BioCardia set a Q4 2026 goal for a Shonin submission to Japan’s PMDA for CardiAMP cell therapy in ischemic HFrEF.Planning initial Japan commercialization around a 20,000-patient subgroup of an estimated 300,000 ischemic heart-failure population.Targeting U.S. enrollment acceleration for the CardiAMP HF II confirmatory trial, positioned for potential FDA Premarket Approval support.Seeking partnerships to expand Helix and Heart3D as a delivery platform for cardiac gene and cell therapies, citing eight active discussions.Advancing licensing options for an allogeneic MSC platform with two FDA INDs, positioned for cardiac and pulmonary indications.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL1QQBhw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BN0W2V16.EUR","LU2095319765.USD","BCDA","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014039.USD","BK4139","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","SG9999014005.SGD","BK4585","SG9999014021.USD","NDAQ","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014013.SGD","BK4588","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083307","title":"BioCardia publishes 2026 shareholder letter outlining priorities, strategic opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083307","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644083307?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:02","pubTimestamp":1781784168,"startTime":"0","endTime":"0","summary":"BioCardia outlined 2026 priorities in a shareholder letter, led by a planned Japan PMDA Shonin submission for CardiAMP Cell Therapy in Q4 2026.Japan launch opportunity framed around about 300,000 ischemic heart failure patients, with initial approval expected to target about 20,000.Letter cited prior Japan reimbursement of USD 124,000 per procedure for chronic ischemic heart failure cell therapies.US focus remains enrollment of the confirmatory CardiAMP HF II trial, which FDA has indicated may support Premarket Approval.Strategy also targets partnering for Helix/Heart3D cardiac delivery platform, with eight early-stage gene or cell therapy discussions cited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the or","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL7q4fDN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644008338","title":"BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2644008338","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644008338?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:00","pubTimestamp":1781784001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nTUA3GFR9P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642260029","title":"BioCardia wins Nasdaq extension to Oct. 7 to meet $2.5 million equity rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2642260029","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642260029?lang=en_us&edition=fundamental","pubTime":"2026-06-12 20:02","pubTimestamp":1781265736,"startTime":"0","endTime":"0","summary":"BioCardia received a Nasdaq notice that stockholders’ equity fell below the USD 2.5 million minimum under Listing Rule 5550.Nasdaq granted an extension to Oct. 7, 2026 to regain compliance following submission of a plan on May 25, 2026.BioCardia raised USD 4.9 million net via an at-the-market sale of 4,004,330 shares at an average USD 1.27 from April 1 to June 5, 2026.BioCardia believes stockholders’ equity now exceeds USD 2.5 million; Nasdaq will monitor compliance at the next periodic report.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL2FRYCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642541882","title":"BioCardia CEO Peter Altman acquires 5,000 common shares valued at $4,250","url":"https://stock-news.laohu8.com/highlight/detail?id=2642541882","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642541882?lang=en_us&edition=fundamental","pubTime":"2026-06-10 05:37","pubTimestamp":1781041074,"startTime":"0","endTime":"0","summary":"BioCardia President and CEO Peter Altman bought 5,000 common shares at USD 0.85.Altman’s direct holding rose to 298,266 shares following the purchase.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260609:nNDL9sWShN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia CEO Peter Altman acquires 5,000 common shares valued at $4,250","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642461030","title":"BioCardia Price Target Maintained With a $25.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2642461030","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642461030?lang=en_us&edition=fundamental","pubTime":"2026-06-09 18:44","pubTimestamp":1781001840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCDA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2026 06:44 ET (10:44 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148419","title":"BioCardia Raises $4.4 Million to Extend Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148419","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641148419?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:38","pubTimestamp":1780922306,"startTime":"0","endTime":"0","summary":"BioCardia ( ($BCDA) ) has shared an update. On June 8, 2026, BioCardia announced it had raised approximately $4.4 million by selling 3,509,604 shar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-raises-4-4-million-to-extend-cash-runway?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-raises-4-4-million-to-extend-cash-runway?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641481986","title":"BioCardia - Net Proceeds Expected to Extend Cash Runway Into Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2641481986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641481986?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:00","pubTimestamp":1780920003,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nTUA6TBC6C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641481698","title":"Press Release: BioCardia Announces $4.4 Million Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641481698","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641481698?lang=en_us&edition=fundamental","pubTime":"2026-06-08 20:00","pubTimestamp":1780920000,"startTime":"0","endTime":"0","summary":"Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into first commercial sales.SUNNYVALE, Calif., June 08, 2026  -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, sold 3,509,604 shares at an average price of $1.279 on Friday, June 5, 2026. No warrants were issued in this capital raise.BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP  autologous and CardiALLO allogeneic cell therapies are the Company's biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are e","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","BK4099","03160","BK4588","R","BCDA","BK4022","BK4604","BK4139","TM","BK4585","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641614762","title":"Sector Update: Healthcare Stocks Higher Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2641614762","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641614762?lang=en_us&edition=fundamental","pubTime":"2026-06-06 03:49","pubTimestamp":1780688942,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.6% and the State Street Health Care Select Sector SPDR ETF  adding 0.7%.The iShares Biotechnology ETF  declined 1.6%.In corporate news, Haemonetics  updated its financial reporting structure and will transition to two segments from three starting in Q1 fiscal 2027. The stock rose 1.8%.BioCardia  received confirmation from the US Food and Drug Administration that its ongoing trial may support a premarket approval of the CardiAMP Cell Therapy System for the treatment of ischemic heart failure with reduced ejection fraction. BioCardia shares climbed 23%.CareCloud  said shareholders approved all proposals put forward at the annual investor meeting on Thursday, including the re-election of Mahmud Haq and Cameron Munter to the board. CareCloud shares fell 1.5%.Vivos Therapeutics  entered a deal with its senior secured lender, Streeterville Capital, to exchange up to $4.5 million of its outstanding debt f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1169590202.USD","LU0128526141.USD","HCSG","LU0029874061.USD","LU0205193047.USD","XLV","LU0012050646.USD","BK4196","LU0106261612.USD","BK4139","CCLD","LU0205194284.USD","IE00B64QTZ34.USD","BK4581","BCDA","IE00B19Z6F94.USD","BK4167","LABU","BK4137","BK4585","BK4198","IE00BLDYK493.USD","IE0034390439.USD","LU1169589451.USD","XBI","VVOS","IBB","HAE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocardia.com","stockEarnings":[{"period":"1week","weight":-0.0305},{"period":"1month","weight":-0.3074},{"period":"3month","weight":-0.2575},{"period":"6month","weight":-0.3299},{"period":"1year","weight":-0.6149},{"period":"ytd","weight":-0.3406}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.066663},{"month":2,"riseRate":0.5,"avgChangeRate":-0.017269},{"month":3,"riseRate":0.25,"avgChangeRate":-0.022375},{"month":4,"riseRate":0.375,"avgChangeRate":0.007226},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.09523},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.005776},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.051846},{"month":8,"riseRate":0.25,"avgChangeRate":-0.102769},{"month":9,"riseRate":0.375,"avgChangeRate":0.008782},{"month":10,"riseRate":0.375,"avgChangeRate":-0.049332},{"month":11,"riseRate":0.5,"avgChangeRate":0.042585},{"month":12,"riseRate":0.375,"avgChangeRate":-0.012187}],"exchange":"NASDAQ","name":"BioCardia","nameEN":"BioCardia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioCardia,BCDA,BioCardia股票,BioCardia股票老虎,BioCardia股票老虎国际,BioCardia行情,BioCardia股票行情,BioCardia股价,BioCardia股市,BioCardia股票价格,BioCardia股票交易,BioCardia股票购买,BioCardia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}